Samples from 19 patients with rheumatoid arthritis (RA) and 15 healthy individuals were included as controls. There was a significant increase in both total PYK2 protein and its activated/phosphorylated form in PBMCs from patients with SLE, particularly in those with the complication of World Health Organization class IV lupus nephritis. There was a clear correlation between the activation of PYK2 and the level of serum complement, but no relationship was found between the activation of PYK2 and SLE Disease Activity Index (SLEDAI). As previous studies have shown that PYK2 provides important signals during the activation of lymphocytes, PYK2 could be a major contributor to the complex autoimmune pathogenesis of SLE.
Introduction
The proline-rich tyrosine kinase 2 (PYK2) is a non-receptor protein tyrosine kinase that is structurally related to focal adhesion kinase (FAK). 1 Unlike the ubiquitous expression of prototype FAK, PYK2 is primarily expressed in populations of neuronal and haematopoetic cells. 2 PYK2 becomes activated in response to stimulation through a number of receptors including integrins, 3,4 cytokine receptors, 5 -7 and lymphocyte antigen receptors. 8 -10 Numerous studies have shown that PYK2 provides important signals during the activation of lymphocytes. 11 -14 Systemic lupus erythematosus (SLE) is a representative systemic autoimmune disease characterized by activated T-cells and polyclonally activated B-cells that produce autoantibodies; the activation of autoreactive T-cells and B-cells plays a pivotal role in the pathogenesis of this M Wang, W Zhang, Y Zhang PYK2 expression and activation in PBMCs from SLE patients disease. 15, 16 Although PYK2 is an important signalling molecule involved in the activation of lymphocytes, the exact role of up-regulation and activation of PYK2 in PBMCs in SLE patients remains unclear.
This study was designed to investigate the up-regulation and activation of PYK2 in PBMCs from patients with SLE compared with PBMC from patients with rheumatoid arthritis (RA) and healthy controls, and whether there were correlations between the hyper-activation of PYK2 protein and the complications of nephritis and levels of serum complements.
Patients and methods

PATIENTS
This observational study included patients with SLE and RA who fulfilled the diagnostic criteria of the American College of Rheumatology (ACR) for the classification of SLE or RA, 17, 18 and who were admitted to the Department of Rheumatology and Immunology, Shandong Provincial Hospital, Jinan, China, between 2006 and 2008. Healthy volunteers were included as controls. The study protocol was approved by the Human Ethics Review Committee of Shandong Provincial Hospital, Jinan, China, and a signed consent form was obtained from each subject prior to their participation in the study.
Activity of SLE disease was evaluated by the SLE Disease Activity Index (SLEDAI). 19 Patients were classified as having inactive disease if SLEDAI was persistently ≤ 9 for ≤ 3 months prior to the study. Patients with active disease had a SLEDAI of ≥ 10 at the time of the study. Patients were also evaluated for lupus nephritis, classified according to the World Health Organization (WHO) criteria I -VI. 20 At the start of the study, all enrolled patients with RA had their swollen joint count and tender/painful joint count recorded, as well as the erythrocyte sedimentation rate (Westergren).
ISOLATION OF PBMCs
Peripheral blood mononuclear cells (PBMCs) from healthy volunteers, RA patients and SLE patients were isolated from 20 ml of heparinized peripheral blood using Ficoll-Paque (Invitrogen, Carlsbad, CA, USA) gradient centrifugation at 500 g for 20 min and then washed twice with 10 mM phosphate buffered saline (PBS), pH 7.2.
WESTERN BLOTTING
Freshly isolated PBMCs (2 × 10 6 cells) were lysed in 200 µl of cold lysis buffer (1% Triton X-100, 0.5% NP-40, 150 mM sodium chloride, 10 mM Tris [pH 7.4], 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene glycol tetraacetic acid, 0.2 mM sodium vanadate, 10 mM sodium fluoride, 0.2 mM phenylmethanesulphonylfluoride and a protease inhibitor mixture) and kept on ice on a shaking platform for 30 min. After centrifugation at 1000 g for 10 min, supernatants were transferred to a fresh tube and stored at -80°C. Protein concentration was determined using the BCA Protein Assay Kit (Santa Cruz Biotechnology, Santa Cruz CA, USA). From each sample preparation, 80 µg of total protein was mixed in Laemmli loading buffer, boiled for 4 min, separated using 8% sodium dodecyl sulphatepolyacrylamide gel electrophoresis and then transferred to polyvinylidene fluoride blotting membranes (Gelman, New York, NY, USA). Membranes were blocked with Trisbuffered saline-Tween/1% bovine serum albumin/1% non-fat dried milk and incubated with rabbit polyclonal antibodies specific for PYK2 (SC-9019), phospho-PYK2 (p-PYK2; SC-11767-R) and β-actin (SC-1616-R) (all from Santa Cruz Biotechnology) overnight at 4°C (diluted according to the M Wang, W Zhang, Y Zhang PYK2 expression and activation in PBMCs from SLE patients manufacturer's instructions). The polyclonal PYK2-specific antibody was used to detect the total protein level of PYK2 while the p-PYK2 antibody, which specifically recognizes PYK2 phosphorylation on tyrosine 402, was used to detect the activation of PYK2. β-Actin was used as a loading control to ensure equal amounts of protein in all lanes. After a final incubation with a 1:5000 dilution of horseradish peroxidase (HRP)-conjugated secondary antibodies (Zhongshan Biotechnology, Beijing, China) for 2 h at room temperature, the membranes were developed using the ECL™ (enhanced chemiluminescence)
Detection System (Santa Cruz Biotechnology). For re-probing, the membranes were stripped in 0.2 M glycine (pH 2.5)/0.05% Tween-20 at 80°C for 20 min, followed by washing, blocking and antibody incubation as described above.
IMMUNOCYTOCHEMISTRY
Single immunoenzyme staining was performed using the biotin-streptavidin peroxidase method with an LSAB™/HRP kit (K0690;
Dako, Glostrup, Denmark) according to the manufacturer's instructions. Briefly, freshly isolated PBMC suspensions were put on glass slides, air-dried for at least 2 h and then immediately stained. Cells were fixed/permeabilized with BD Cytofix/ Cytoperm™ solution (BD Biosciences, USA) solution for 20 min at 4°C, dried and then washed twice in 10 mM PBS, pH 7.2, for 5 min. The fixed cells were then incubated with blocking solution (LSAB kit component) for 5 min in a humid atmosphere prior to the addition of primary antibody specific for p-PYK2 (SC-11767-R) at the appropriate dilution (1:100) and incubation for 30 min in a humid atmosphere at room temperature. After rinsing in 10 mM PBS (pH 7.2), the cells were allowed to react for 10 min with biotinylated anti-rabbit antibody (LSAB kit component), and then rinsed and incubated with streptavidin-horseradish peroxidase (LSAB kit component) for 30 min. The cells were developed in diaminobenzidine and the reaction was stopped by dipping the slides in distilled water. The cells were counterstained with 1% haematoxylin, covered with a cover slip and examined under a light microscope. Positive cells were counted in a blinded fashion at ×400 magnification in 10 randomly chosen fields by two independent observers. The mean from the two observers was calculated to obtain the percentage of positive cells per sample.
STATISTICAL ANALYSIS
Data were expressed as the mean ± SD. Differences were examined for statistical significance by the Mann-Whitney U-test. Analysis of correlations between variables was based on Pearson's rank test. A P-value < 0.05 was considered to be statistically significant. The data set was analysed using SPSS ® version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Each experiment was repeated at least three times to assess reproducibility. All patients fulfilled the diagnostic criteria of the American College of Rheumatology for the classification of SLE or RA. 17, 18 Ten M Wang, W Zhang, Y Zhang PYK2 expression and activation in PBMCs from SLE patients patients, nine of whom had newlydiagnosed SLE, were receiving no treatment at the time of the study. Twenty-six SLE patients were receiving low-dose steroids (≤ 10 mg/day prednisolone) and/or immunosuppressive agents (cyclophosphamide). None of the SLE patients was receiving prednisolone at a dosage of ≥ 10 mg/day. Twenty-two patients had biopsy-proven proliferative lupus nephritis WHO class IV 20 , six had WHO class II nephritis, three had WHO class V nephritis, five had WHO class I nephritis and four had central nervous system (CNS) manifestations. All enrolled patients with RA had > 6 swollen joints, > 6 tender joints and an erythrocyte sedimentation rate (Westergren) of > 30 mm/h at the time of the study.
Results
PATIENTS
PYK2 IS INCREASED AND ACTIVATED IN PBMCS FROM SLE PATIENTS
To see the pattern of expression and activation of PYK2 in PBMCs, Western blotting was used to evaluate total PYK2 and p-PYK2 in freshly-isolated PBMCs from SLE patients, RA patients and healthy controls. As shown in Fig. 1A (top) , the intensity of the PYK2 band in PBMCs from SLE patients was higher than for either healthy controls or patients with RA. Quantitative analysis showed that total PYK2 protein in PBMCs was significantly up-regulated in patients with inactive and active SLE (mean ± SD [arbitrary units] 1.11 ± 0.14 and 1.26 ± 0.11, respectively) compared with patients with RA (0.95 ± 0.22) or healthy controls (0.93 ± 0.13) (P < 0.05; Fig. 1B ). While PYK2 was weakly phosphorylated on the tyrosine 402 residue in healthy donors and RA patients, a consistently much thicker band corresponding to p-PYK2 was seen for SLE patients (Fig. 1A [middle] ). This was further verified by quantitative analysis showing that the level of p-PYK2 was significantly higher in PBMCs from patients with inactive and active SLE (mean ± SD 0.98 ± 0.18 and 1.08 ± 0.10, respectively) compared with patients with RA (0.81 ± 0.08), or healthy controls (0.77 ± 0.13) (P < 0.05; Fig. 1B) .
In order to confirm the result of the above experiment, PBMCs from SLE patients, RA patients and healthy controls were immunostained with an antibody against p-PYK2. As shown in Fig. 2 , p-PYK2 was not detectable in lymphocytes from healthy donors or RA patients, whereas in lymphocytes from SLE patients, both the intensity and the proportion of p-PYK2 immunostaining were increased. These data further confirmed the results obtained by Western blotting.
P-PYK2 IS EXCLUSIVELY UPREGULATED IN SLE PATIENTS WITH CLASS IV LUPUS NEPHRITIS
The correlation between levels of p-PYK2 and the clinical complications of SLE were assessed. As shown in Fig. 3A , the expression of p-PYK2 was significantly up-regulated in PBMCs from SLE patients with WHO class IV lupus nephritis (P < 0.05), whereas this upregulation was not seen in either healthy donors or SLE patients with CNS disease or those with nephritis other than WHO class IV.
P-PYK2 WAS NEGATIVELY CORRELATED WITH SERUM COMPLEMENT IN SLE PATIENTS
To give further characterization of the correlation between levels of activated PYK2 and the clinical manifestations of SLE, p-PYK2 levels were examined with respect to the level of total serum complement activity (CH50) and a significant negative correlation was found for the total cohort of M Wang, W Zhang, Y Zhang PYK2 expression and activation in PBMCs from SLE patients SLE patients (r = -0.668, P < 0.01) (Fig. 3B) . The activation of PYK2 was not correlated with SLEDAI (data not shown).
Discussion
The present study demonstrated upregulation of PYK2 in the PBMCs of SLE patients and showed hyper-activation of PYK2 in SLE patients with WHO class IV lupus nephritis. This hyper-activation was also shown to be negatively correlated with the level of serum complement. This is the first study, to our knowledge, to demonstrate that PYK2 expression and activation appear exclusively in SLE PBMCs and might be crucial for the pathogenesis of SLE, particularly for the development of nephritis.
Furthermore, the present study showed no up-regulation or activation of p-PYK2 in PBMCs from RA patients or healthy controls, which confirms results from a previous study by Shahrara et al. 21 which also showed no only up-regulation but also phosphorylation at tyrosine 402 residues for PYK2 in SLE PBMCs was shown in the present study, which suggests that the activation of PYK2 may not only be functionally enhanced in SLE but might also be a process specific to SLE.
It has been reported that PYK2 is overexpressed in glomeruli but not in other tissues of human and rat crescentic glomerulonephritis, and that this is closely associated with the onset of glomerulonephritis. 22 In the present study, a marked up-regulation of p-PYK2 was observed in PBMCs from SLE patients with WHO class IV lupus nephritis, but not in healthy controls, RA patients or SLE patients with CNS disease or nephritis other than WHO class IV. Furthermore, a clear negative correlation between the levels of p-PYK2 and serum CH50 was found, suggesting that signalling pathways involving PYK2 are likely to play a role in the development and progression of nephritis.
The present study, together with earlier studies, demonstrated that PBMCs from SLE patients exhibit both increased expression and enhanced activity of PYK2, and that the level of p-PYK2 in SLE PBMCs correlates with the development of WHO class IV lupus nephritis. Although these findings did not determine M Wang, W Zhang, Y Zhang PYK2 expression and activation in PBMCs from SLE patients whether or not increased activation of PYK2 is a primary event for SLE PBMC proliferation, further understanding of this pathway may be important in gaining new insights into the factors that promote activation of autoreactive T-and B-cells in SLE. 
